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such as frontalhypoperfusionandasymmetricinvolvement
of the cerebral cortex have been observed (7,8), the pres
ence of hypoperfusion in the temporo-parietal areas dem
onstrated by SPECT and @â€œ@Tc-hexamethylpropylena
mine oxime (@Tc-HMPAO) has a high predictive value
for the presence of AD in patients with memory and cog
nitive impairment (8).
The use of SPEC!' in clinical practice is facilitated by its
lower costs and its wide diffusioncompared to other tech
niques such as PET. On the other hand, the reliability of
SPECT findings has always been limited by the relatively
poor spatial resolution of circular shaped rotating gamma
cameras and the low brain uptake values of the tracers
used (9). With the development of new high-resolution
SPEcT systems, both spatial resolution and detection ef
ficiency oftomographic imaging are improved compared to
single-head rotating gamma camera systems (10), thus al
lowing a better image quality and improving the quantifi
cation of regional radioactivity. However, the improve
ment in image quality obtained by high-resolution SPECT
does not diminish the limitations related to the kinetics of
the tracers used (11).
PET is a more accurate technique than SPECT with
regardto resolution and quantitativeaccuracy (12,13) and
it should be regarded as the reference technique for the
assessment of regional brain function. A reduction of glu
cose metabolism measured with PET and 18F-fluoro-2-
deoxy-D-glucose (â€˜8F-FDG)in the temporo-parietal cortex
has been consistently shown in patients with mild to mod
crate probableAD (14â€”16),althoughother patternsof glu
cose metabolism such as frontal (17) or asymmetric in
volvement of the cerebral cortex (18â€”21) have also been
observed. Although PET has been successfully used to
assess the metabolic function in patients with probable
AD, its applicability to clinical practice is limited by the
high costs; indeed PET has now been mostly used for
research purposes.
The aim of this study was to carry out a systematic
evaluationof PETversus SPECT in patientswith early AD
SPECT studies of regionalcerebral perfusionwItha high-reso
Iutlonsystem were comparedto PETstudies of regionalcerebral
glucoseutilization(rCMRgk@)in21patientswfthprobableAlzhei
mar'sdisease(AD).Ten normalsubjectswerealsoeValUated
wfthSPECTand10w@iPET.Methods:rCMRgIc(forPET)and
counts(forSPECT)in theassociativecor@ceswerenormalized
totheaveragerCMRgIc,andcountsinthecalcatinecortexand
basalgangliawereconsideredasa â€œreferenceareaâ€•to obtaina
ratio.The ratiodifferencesbetweenpatientsandcontrolswere
testedw@iANOVAperformedseparatelyfor PETandSPECT.
Results:ThedifferencebetweenprobableADpatientsandcon
tmls was significantfor bofhPET (p < 0.00001)and SPECT
(p < 0.005);thisdifferencewassignificantfor the frontal,tern
poraland parietalcortices(p < 0.0001)for PET,and for the
temporal(p < 0.005)and patietal (p < 0.001)cor@cesfor
SPECT.Temporo-pailetaldefectsweredetectedin all subjects
with PET and in 90% with SPECT.Conclusion: PET and
SPECTareabletodetectharacteristicternporo-parietalabnor
malitiesinprobableAD.However,thepresenceofabnormalities
inotherassociativeareasisbetterevaluatedwithPET.
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he assessment of cerebral perfusion with SPECT is
being increasinglyused in the routine clinical evaluation of
neurological and psychiatric disorders (1).
The clinical relevance of SPECF studies in the evalua
tion of patients with probable Alzheimer's disease in the
early phase is related to the evidence of an abnormal pat
tern of perfusion (Le., hypoperfusion of the temporo-pari
etal cortex) consistently detected by SPECT studies of
blood flow in these patients (2â€”6).Although other patterns,
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Sex (yr)(mo) MMSEMRI (days)
resolution SPECF study with @Tc-HMPAO.The average time
between PET and high-resolution SPECF examinations was 11.7
Â±21.7 days (Table 1) and the order of the exams was random.
Normal controls for the PET study were 3 males and 7 females
(mean age 47 Â±13yr), while normal controls for the high-resolu
tionSPECFstudywere4 malesand6 females(meanage53 Â±
13yr). All controlswerefreefromknownneuroloajcaldiseases,
includingcerebrovasculardiseaseas assessedby clinicalhistory,
standardclinicalandneurologicalexaminationsandneuropsycho
logicaltesting(MMSE).
The protocolwas approvedby the EthicsCommitteeof the
ScientificInstitute H. San Raffaele.Informedconsent was ob
tamed from each subject.
PETImaging
PET studies were performed with a PET tomograph (931fi14-12
CPS/Siemens, Erlangen, Germany)with a spatial resolution equal
to 6.3 mm fullwidth at half maximum (FWHM) in the axial image
plane.Thetomographadanaxialfieldof view of 5.4 cmwhich
yieldedsevenaxialimageslices675 mmthick(23).
Thepatientsrestedon thebed in a dimroom,eyes openand
ears unplugged,with their head positioned in a special head
holderwhichusesthesubject'sdentalmorphologyforpositioning
and fixation(24). In some patients, a personalmoldedfoamwas
used to fix the head.
Thesynthesisandqualitycontrolof â€˜8F-FDGwas carnedout
accordingto standardprocedures(25). Fourteen images,parallel
to theorbito-meatalline,wereacquired45 mmafterthe intrave
nous injection of approximately 250-300 MBq of â€˜8F-FDOwith
two spatially contiguous emission scans, each lasting 10 mm, in
orderto examinethe whole brain.Duringscanning,approxi
mately 14millioncounts were acquired.
Axial slices were reconstructed employing a Hann filter with a
cut-offfrequencyof 0.5 cycles/pixel(matrix 128x 128).Photon
attenuationwas correctedby use of coefficients determinedfrom
two transmissionscans, one for each bed position,obtainedwith
a @Gef@Gaexternalringsource,lasting10mmeach,priorto the
18Fp@ injection.
Plasma 18F-FDO and glucose time-activity curves (input func
tions) were obtained by blood sampling from the radial artery at
approximately3-sec intervalsfor the first minute after injection
andatprogressivelylongerintervalsforthedurationof theentire
study.
Valuesof re@onalcerebralmetabolicrateof glucose(rCMRglc)
were calculated according to the method based upon the autora
diographictechniqueofSokoloffet al. (26)andrevisedby Reivich
et al. (27)forhumanPETstudies.
High-RISOIUtIOnSPECTImaging
High-resolutionSPECF imagingwas performedwith an annu
lar SPECF system (CERASPECFâ€”Digital Scintigraphic Inc.,
Maynard, MA) (28) with a spatial resolution equal to 8.4 mm
FWHM in the center of the axial plane. The system covered an
axial field ofview of 10.5cm. As with PET, the patients rested on
a bed in a quiet room at the time of injection. The patient's head
was positioned in a head-holderspecificallybuilt for the
CERASPECFmachine.
Images parallel to the orbito-meatal line were acquired beghi
ning 15mm after intravenous injection of approximately 740-800
MBq of@Fc-HMPAO. In 30 mm, 7 to 9 million total counts were
acquired for the entire head, using a square pixel size equal to 1.66
mm and an angular step of 3Â°over 360Â°(matrix size 128 x 64 and
120projections).
TABLE I
Patients'clinicalData
I F 59 12 20 Atrophy
2 M 57 24 19 Atrophy
3 M 57 24 16 Norm@
4 M 67 36 22 Atrophy+wm
5 M 62 24 20 Atrophy
6 M 60 12 15 Atrophy
7 F 70 5 14 Atrophy
8 F 77 24 25 Atrophy
9 F 73 29 29 Atrophy
10 F 74 24 21 Wm
11 M 57 24 24 Atrophy
12 M 66 36 19 Atrophy
13 F 52 12 22 Atrophy+wm
14 N 64 36 14 Atrophy
15 F 60 24 23 Normal
16 M 63 24 23 Atrophy
17 F 62 6 29 Atrophy
18 F 44 24 14 Normal
19 M 68 36 24 Atrophy
20 F 69 24 12 Atrophy
21 F 58 36 12 Atrophy
MMSE= minimentalstatexamination;@tt= timeelapsedbetween
PETand SPECTstudIes; Atrophy - m@ddegree ofatrophy wm = smal
lesionsof thewhitematter.
with the purpose of evaluating, in the same patients, the
relative ability of high-resolutionSPECF with @Tc-HM
PAO in comparisonwith PET and â€˜8F-FDGto differentiate
patients in the early phase of the disease from normal
controls and to detect abnormalities that are considered
characteristic of probable AD patients, such as temporo
parietal impairment.
MATERIALS AND METHODS
Sub@ts
Twenty-one patients with probable AD (10 males, 11 females,
mean age 62.8 Â±7.8 yr) were studied. The main clinical and
radiological features of these patients are reported in Table 1.
Allpatientswere clinicallydiagnosedas probableAD (average
durationof illness 23.6 Â±9.6 mo) according to standardcriteria
(22). Other causes of dementia were excluded through neurolog
ical examinationand laboratoryblood tests. The severityof the
disease, assessed with the Mini Mental State Examination
(MMSE), was mild to moderate (MMSE mean score 19.8 Â±5;
Table 1).
An MRI study was performed in all patients with a 1.5 T
scanner (Magnetom, Siemens, Enrlangen, Germany). A mild de
gree of generalizedatrophy was observed in 16t21patients and
smalllesionsofthe whitematter,probablydue tovascularlacunar
lesions, were present in 3t21patients (Table 1).
At the timeof the PETandhigh-resolutionSPECTexamina
lions, patients were free from pharmacological treatments known
to alter cerebralperfusion and metabolism.
Allpatientsunderwenta PET studywith â€˜8F-FDGand a high
2
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Region PET AD PET N@ SPECT ADSPECTNAssociative
frontal 0.796 Â±0.092k 0.962 Â±0.024 0.828 Â±0.1020.887 Â±0.034Meslal
frontal 0.792 Â±0.071@ 0.933 Â±0.043 0.871 Â±0.0920.889 Â±0.054Temporal
0.708 Â±0.061k 0.830 Â±0.057 0.839 Â±O.O76@0.910 Â±0.034Pailetai
0.704 Â±0.080k 0.943 Â±0.030 0.838 Â±0.101@0.960 Â±0.040Lateral
occipital 0.826 Â±0.116 0.918 Â±0.073 0.983 Â±0.1091 .026 Â±0.046Thalamus
0.958 Â±0.074 0.951 Â±0.054 1.031 Â±0.0860.995 Â±0.080Cerebellum
0.830 Â±0.082 0.856 Â±0.042 1.198Â±0.121.154 Â±0.075(0)
@ft and right hemispheres ratios are averaged. AD = Alzheimer's disease; N = normalcontrols.*
= p <0.0001.t
= p <0.005.*
= p < 0.001.
TABLE 2
PETandHigh-ResolutionSPECTRalioValues(Â°)in ProbableAlzheimer'sDiseasePatientsandNormalControls
Sixty-fouraxialslices, 1.66mmthick,were reconstructedusing
a Harm filter with a cut-off frequency of 0.5 cycles/pixel. The
reconstructed images were corrected for attenuation with the
Chang's first order method (29) with an attenuation coefficient
equal to 0.1 cm'. Four consecutive axial slices were added
together in orderto obtain a slice thickness of 6.64 mm, similarto
thatof thePETimages.
DataAnalysis
PET andhigh-resolutionSPECF imageanalysiswas performed
on a SUN (SPARC) workstation. Circular regions of interest
(ROIs,diameter= 1.5theFWHMof therespectivesystem)were
manuallypositionedon allthecorticalandsubcorticalstructures
and on the cerebellar hemispheres. Mean rCMRglcvalues (for
PET)andmeancounts (forSPECF)were calculatedforeachROI
and these values were simply averaged to obtain values of nine
anatomo-functional areas identified according to the Damasio and
Damasio atlas (30). This atlas is particularly suitable to examine
cortical activity of associative areas (typically damaged in AD)
and it has been previously used to evaluate PET and SPECT
patterns in patients with cognitive deficits (31,32). The areas cx
amined were the associative frontal, mesial frontal, temporal,
parietal, lateraloccipital and calcarinecortices, the thalamus,the
basal ganglia (head of caudate and putamen) and the cerebellar
cortex. Since the calcarine cortex and basal ganglia are generally
spared in probableAD (33), mean rCMRglcand meancounts of
the calcarine cortex and the basal gangliawere taken as the least
affected areas and averaged to obtain a reference value (Aref) for
normalizationof brain activity. Data were then analyzed in the
form of ratios determined as follows:
Ratio = Ar/Aref,
where Ar equals rCMRglcfor PET studies and counts for high
resolutionSPECF studies in each anatomo-functionalregion, and
Aref equals average rCMRglc for PET studies and average counts
for high-resolutionSPECT studies in the referenceareas, i.e., the
calcarine cortex and the basal ganglia.
StaUsticalAnalysis
PET and high-resolutionSPECT ratiovalues obtainedin prob
able AD patientswere comparedwith the respective ratiovalues
obtained in normalcontrols.
The groupdifferenceswere evaluatedusing a factorialanalysis
of variance (ANOVA) with two between-level factors (probable
AD and control subjects) and two within-subject factors (cerebral
regions, i.e., the ratios obtained for the anatomo-functional areas
identifiedandlisted in Table2, andcerebralhemispheres, i.e., left
and right). This analysis was repeated separately for PET and
high-resolution SPECT.
An individual analysis was also performed considering ratio
values of rCMRglcand counts in each patientas abnormalwhen
beyond the 99% confidence interval of the control group ratio
values.
RESULTS
The mean ratio values and standard deviations of PET
and high-resolution SPEC!' regional values of probable AD
and normals are reported in Table 2.
For PET studies, the ANOVA showed that both the
group effect (F = 49.9, df = 1, p < 0.00001) and the region
effect (F = 21.7, df = 6, p < 0.00001) were significant,
whereas the hemisphere effect was not significant. The
group x region interaction was significant (F = 12, df = 6,
p < 0.00001). This was further analyzed by simple main
effects which showed high significant difference (p <
0.0001) for the associative and mesial frontal cortex, the
parietal and temporal cortices, whereas the difference was
not significant for the lateral occipital cortex, the thalamus
and the cerebellum (Table 2).
For high-resolutionSPECT studies, there was a signifi
cant difference between groups (F = 9, df = 1, p < 0.005)
and between regions (F = 48, df = 6, p < 0.00001),
whereas the difference between sides was not significant
(F = 3.2, df = 1, n.s.). The group x region interactionwas
significant (F = 3.2, df = 6, p < 0.005) and the simple main
effects analysis showed significant differences for the pan
etal (p < 0.001) and the temporal (p < 0.005) cortices
(Table 2). A typical PET and high-resolution SPEC1' pat
tern of bilateral temporo-parietal abnormalities is shown in
Figure 1.
The results obtained with the individual analysis are
represented in Figure 2 where the ratio values of the pan
etal, temporal and associative frontal contices of the left
and right hemispheres are reported. Metabolism or perfu
sion were considered abnormal when the regional values
(either of the right or left hemisphere or both) were out of
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FiGURE I. Cerebral glucose metabolismusing PET with
[18flp@ (toprow)and perfusionusinghigh-resolutionSPECTwith
@rc-HMPAOrespectively(bottomrow)Inonepatientwithproba
bleAD (Patient3, Table 1).Two tomographklevelsparallelto the
orbito-meatalinethroughthe midandcranialpartsof the brainare
represented. Images are displayed with respect to the madmum
valueofeechstudy(PETandSPECT).Bothstudiesshowmarked
reductionof metabolismin the temporaland parietalcortices,more
markedinthenghtside.Notethepreservationof metabolismand
perfusioninthecalcarinecortexandInthebasalganglia,whichare
well depictedInbothstudies.
the mean Â±2 s.d. of the control group. In the parietal
cortex (Fig. 2A) abnormal values were found in all patients
by PET and in 16/21 patients by high-resolution SPECT'. Of
the five patients who did not show areas of hypoperfusion
in the parietal cortex at high-resolution SPEC!', three
showed hypoperfusion in the temporal cortex and the re
maining two in the frontal cortex. Areas of hypometabo
lism and hypoperfusion were also found in the temporal
cortex (12121with PET and 13,21 with SPECF, Fig. 2B)
and in the associative frontal cortex (18/21with PET and
11/21with SPECT, Fig. 2C).
The percentageof patientswith PET andhigh-resolution
SPECT abnormalities is shown in Table 3. When temporal
and parietalregions of the left and righthemispheres were
combined, all patients showed hypometabolism with PET
and 19/21(90%)patients showed hypoperfusionwith high
resolution SPECT. The two patients who had normal per
fusion in the temporo-parietal cortex (#19 and #20; Table
1) showeda selectivefrontaldeficit.PET studiesin these
patients showed marked abnormalities in the frontal cor
tex, but also in the parietal lobes (Fig. 3).
As for the presence of interhemispheric asymmetries,
unilateral involvement of the temporo-parietal cortex was
shown only in one patient (#9) by both PET and high
resolution SPECT, although bilateral abnormalities, more
markedon one side, were present in several patients. High
resolution SPEC!' unilateralinvolvement of the temporo
parietal cortex was found in two patients (#5 and #12) in
whom PET demonstrated bilateral hypometabolism more
markedon one side.
S I
I
S
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DISCUSSION
The results of this study demonstrate that areas of sig
nificant reduction of glucose metabolism and blood flow
can be detected by PET and high-resolution SPECT, re
spectively, in the same population of patients with early
probableAD. Although the possible relationship between
PET metabolic changes and SPECF perfusion changes ob
served in several neurological disorders, including demen
FIGURE2. ComparieonoftherelatWevaluesofglucosem tab
olism(PET)andperfusion(high-resolUtiOnSPECI)of eechsingle
probableADpatient(filledsymbols)withthecorrespondingmean
value Â±2s.d. obtained In normal controls (empty symbols) for the
twohemispheres.R = righthemisphere;L = lefthemisphere.The
ratiosbetweenmeanrcMRglc(forPEt) and meancounts(for
high-resolutionSPECT)inthepadetal(A@,temporal(B)andasso
dativefrontalcortices(C),andmeanrCMRglcandcountsInthe
â€œreferenceâ€•areas(averageof calcarinecortexandbasalganglia)
axerepresented.
RegionPETSPECTAssociative
frontal86%52%Meslal
frontal62%24%Temporal62%62%PaÃ±etal100%76%Lateral
occipItal33%28%TernpOro/parletai100%90%
TABLE 3
Percentof PatientswithAbnormalRegions
In this study, abnormalities in the temporo-parietal cor
tex were also detected by high-resolutionSPEC!' in a high
percentage of patients (90%), which is in the range of
previously published data (from 70% to 100%)(35). The
only two patients with a prevalent frontal hypoperfusion on
SPECT showed cortical hypometabolism more marked in
the frontal areas, but diffuse also on the temporo-parietal
areas on PET. In these two cases, Pick's disease or frontal
type dementia cannot be excluded, and the differential
diagnosis between Pick's andAD is based only on autopsy
findings.
The high sensitivity observed in this report might be
related to the availability ofhigh spatial resolution PET and
SPECT systems and to the use of semiquantitative analy
sis, such as the ratio analysis reported here.
The anatomical structure most frequently used for the
semiquantitative ratio analysis of SPEC!' studies is the
cerebellum (3â€”5)In this study, the reference area used in
the ratio was the average activity of the basal ganglia and
the calcarine cortex. We did not choose the cerebellum as
a reference area because of an apparent uncoupling be
tween perfusion and glucose metabolism in the cerebellar
hemispheres. In fact, an overestimation of perfusion oh
tamed with @Tc-HMPAOin the cerebellum compared
with blood flow estimatedwith â€˜8F-fluoromethaneandPET
has been previously reported and it has been attributedto
the high capillaritydensity in the cerebellum (36). Further
more, a cerebralblood flow (CBF) and cerebral metabolic
rate for oxygen (rCMRO@)higherthanglucose metabolism
in normal cerebellum measured with PET has also been
reported by Sasaki et al. (37). Although a comparative
analysis between PET and high-resolution SPECT values
in normal regions was not performed because out of the
purposes of the present work, an indication of higher val
ues of blood flow estimated with @â€˜@â€˜Fc-HMPAOin the
r@i cerebellumcanbeinferredbythedatashowni Table2
where the ratio value of cerebellum m controls measured
with high-resolutionSPECF was 26%higher than the cor
responding value measured with PET@@:i Thecalcarinecortexandbasalgangliawerechosenbe
cause they are usually spared in AD (33) and because the
L use of these structures m the ratios has been recently tested
in a PETIFDG study of AD and nonAD patients (38,39)
and its diagnostic power has been found to be high (sensi
tivity of 92% and specificity of 80%)
A discrepancybetween PET andhigh-resolutionSPECF
findmgs was observed m the detection of abnormalities m
the frontal associative cortex. Whereas in the group anal
ysis, PET metabolic values showed that both the lateral
andmesial frontalcortex was significantlyaffected in prob
able AD, high-resolutionSPED.' regionalvariations in the
frontal cortex, although present in some ofthe patients, did
not reach a statistical significancein the group analysis On
the other hand, in the parietal cortex, abnormalities were
detected by high-resolution SPECF in a smaller number of
patients than by PET (Table 3). Although the defect in the
temporal and the parietal cortex is severe and constant
tia, has been raised (13,34), the present study reports a
systematic comparison of the same series of patients with
probable AD examined with PET and high-resolution
SPECT techniques.
Significant differences between probable AD and con
trols were found in the parietal and temporal cortices both
with PET and high-resolution SPECT. The finding of ab
normalities in the temporo-parietalcortex, present in all
patients by PET, demonstrates the abilityof this technique
to detect a metabolic pattern which is characteristic of
probable AD, consistent with previous reports (14â€”16).
Recently, the sensitivity of PET with â€˜5O-waterto detect
bilateral abnormalities in the temporo-pa.rietal cortex has
been reported to be 38% by Powers et al. (21) in a popu
lation of probable AD patients similar or even more com
promised than the one in the present report. However, in
the study by Powers et aL, the spatial resolution of the
images (18mm FWHM) was lower in comparison with that
of the present PET (63 mm FWHM) and high-resolution
SPEC!' (8.4 mm FWHM) studies because offactors related
to the tracer and PET technology. Furthermore, results
and conclusions were drawn only from visual analysis.
(18F]@G PET
R
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@@@Tc]HMâ€”PAOhrSPET
FIGURE3. ReglonalglucosemetabolismobtainedwithPETand
[18fl@ (toprow)andperfusionobtainedwithhigh-resolution
SPEcT ani @c1HMPAO(bottomrow) In Patient19 (Table1).
Twotomographiclevelsparalleltothe orbito-meatalIhiethroughthe
mid and cranial parts of the brain are represented.Imagesare
displayedwithrespecto themwdmumvalueof eachstudy(PET
and SPECT).Both studiesshow hypometabolismand hypoperfu
sionbilaterally@mthefrontalcoitex.PETaISOshowshypometabolism
of the pailetalcortexbilaterally.
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enough to reach a statistical significance with both tech
niques, the defect in the frontal cortex is less frequent and
does not reach a statistical significance with high-resolution
SPECF. This finding of a slightly lower sensitivity of high
resolution SPECT compared to PET can be caused by
several factors, including physical limitations, such as
lower resolution of high-resolution SPECF compared to
PET, andbiological constraintsdue to the differentkinetics
of the tracers used (12,13).
PET images were obtained with 18F-FDG, a tracer
whose metabolic fate and kinetics are well known Thus,
PET analysis can be done based on data of glucose con
sumption and the information obtained is directly repre
sentative of regional functional activity. For high-resolu
tion SPEC!' studies, we used @â€˜@Tc-HMPAO,a tracerthat
is known to be distributed in the brain in proportion to
cerebral blood flow. Although models to quantify blood
flow with HMPAO have been proposed (40â€”42),they re
quire arterial blood samples and metabolite assays, result
ing in a limitation for wide clinical application of SPECF
studies of demented patients.
In spite of these discrepancies, our findings of similar
patterns of glucose metabolism and perfusion in the same
probableAD patients seem to indicate that a tightrelation
ship between blood flow and glucose metabolism is main
tamed in this disorder, which is consistent with the cou
pling between blood flow and oxygen metabolism
previously demonstrated with PET (43).
CONCLUSION
The results of this study confirmthat: (1) both PET and
high-resolution SPECF identify the characteristic temporo
parietal pattern in the same series of probable AD patients,
with PET being only marginally more accurate than
SPEC!'; and (2) other abnormalities such as frontal in
volvement are better evaluated with PET. The high reso
lution of the systems used as well as the use of either
quantitative or semiquantitative analysis of the emission
tomography data may contribute to the high sensitivity of
the methods. Further development of methods for blood
flow quantificationmay improvethe diagnosticaccuracyof
high-resolution SPECF.
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